Dermot Pearson, Strategic Marketing Director, Novozymes Biopharma UK

Dermot PearsonDermot Pearson is Strategic Marketing Director at Novozymes Biopharma UK with responsibility for market development of their Veltis albumins in half-life extension and oncology drug targeting.  His roles include overseeing product market development, branding, pricing and life cycle management, all on global basis.  A member of business unit management team and in the past has held roles in R&D, Quality and GMP Product Manufacturing.

1. Why did you decide to do a webinar with us?  

We have had excellent previous experience working with BRW to deliver a professional presentation to the industry community most relevant to us.

2. What are you looking forward to discussing with the audience?

The arena of drug improvement for patient benefit in terms of improving the benefit they can derive from improvements in the way the industry develops and delivers novel medicines.

3. What sparked your interest in drug development?

Initially it was the realisation that there was a need for patient therapeutic benefit improvement and that we could play a modest role in this by applying the depth and quality of our scientific knowledge and experience of recombinant albumin to new forms of known drugs, and to those to be developed.

4. What do you most enjoy about your role? 

Complete immersion in deep science and the harnessing of that value to making a business work using our knowledge, all with the added benefit of working closely with our own people and with our customers.

5. Where is your favourite place in the world and why?

So many to choose from it is difficult to narrow it to one.  However if I had to I would plump for rural Tuscany for some of the obvious benefit of wonderful climate and outstanding food and wine.  We regularly take the opportunity to visit to enjoy the pure relaxation offered by the environment there.  Of course places like California and Japan I would have to rate very highly indeed.

Novozymes will be presenting their webinar Differentiated polypeptide dosing for patient adherence‘ on 7th October at 11AM California/ 2PM New York/ 7PM London. Read more and register here.

 

Leave a Reply

Your email address will not be published. Required fields are marked *